Sagimet Biosciences Inc. (SGMT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David A. Happel | CEO, President & Director | 906.16k | -- | 1962 |
| Mr. Thierry Chauche | CFO & Principal Accounting Officer | 598.04k | -- | 1976 |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer | 669.06k | -- | 1963 |
| Mr. Urs Greber Ph.D. | Co-Founder | -- | -- | -- |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder | -- | -- | -- |
| Ms. Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer | -- | -- | 1972 |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development | -- | -- | -- |
| Mr. Robert D'Urso | Senior Vice President of New Products | -- | -- | -- |
Sagimet Biosciences Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Corporate Governance
Upcoming Events
May 8, 2025 at 10:00 AM UTC
Sagimet Biosciences Inc. Earnings Date
Recent Events
August 22, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission